Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing

Journal of Pathology

Volumn 230, Issue 3, 2013, Pages 270-276

  Majewski, Ian J ^a,b   Mittempergher, Lorenza ^a   Davidson, Nadia M ^c   Bosma, Astrid ^a   Willems, Stefan M ^d   Horlings, Hugo M ^e   De Rink, Iris ^a   Greger, Liliana ^f   Hooijer, Gerrit K J ^e   Peters, Dennis ^a   Nederlof, Petra M ^a   Hofland, Ingrid ^a   De Jong, Jeroen ^a   Wesseling, Jelle ^a   Kluin, Roelof J C ^a   Brugman, Wim ^a   Kerkhoven, Ron ^a   Nieboer, Frank ^g   Roepman, Paul ^g   Broeks, Annegien ^a   Muley, Thomas R ^h   Jassem, Jacek ⁱ   Niklinski, Jacek ^j   Van Zandwijk, Nico ^k   Brazma, Alvis ^f   Oshlack, Alicia ^c   Van Den Heuvel, Michel ^a   Bernards, René ^a   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^g Agendia NV   (Netherlands)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^k Asbestos Diseases Research Institute   (Australia)

more..

Author keywords

ALK; FGFR3; FGFR3 TACC3; fusion genes; kinome

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

AMINO ACID SUBSTITUTION; ARTICLE; EXON; FUSION GENE; GENE AMPLIFICATION; GENE FUSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; OPEN READING FRAME; PRIORITY JOURNAL; RECURRENT CANCER; RNA SEQUENCE;

ADENOCARCINOMA; BASE SEQUENCE; CALMODULIN-BINDING PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; EXONS; GENE LIBRARY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; NERVE TISSUE PROTEINS; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SEQUENCE ANALYSIS, RNA;

EID: 84878783802     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4209     Document Type: Article

References (30)

1. Nowell PC, Hungerford DA,. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960; 25: 85-109.
2. Tomlins SA, Rhodes DR, Perner S, et al,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648. (Pubitemid 41528150)
3. Ding L, Getz G, Wheeler DA, et al,. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
4. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
5. Imielinski M, Berger AH, Hammerman PS, et al,. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-1120.
6. Peifer M, Fernandez-Cuesta L, Sos ML, et al,. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genet 2012; 44: 1104-1110.
7. Rudin CM, Durinck S, Stawiski EW, et al,. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genet 2012; 44: 1111-1116.
8. Seo JS, Ju YS, Lee WC, et al,. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012; 22: 2109-2119.
9. Soda M, Choi YL, Enomoto M, et al,. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566. (Pubitemid 47206930)
10. Shaw AT, Yeap BY, Solomon BJ, et al,. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012.
11. Bergethon K, Shaw AT, Ou SH, et al,. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-870.
12. Takeuchi K, Soda M, Togashi Y, et al,. RET, ROS1 and ALK fusions in lung cancer. Nature Med 2012; 18: 378-381.
13. Roepman P, Jassem J, Smit EF, et al,. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009; 15: 284-290.
14. Trapnell C, Pachter L, Salzberg SL,. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-1111.
15. Li H, Handsaker B, Wysoker A, et al,. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
16. Kim D, Salzberg SL,. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 2011; 12: R72.
17. McPherson A, Hormozdiari F, Zayed A, et al,. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011; 7: e1001138.
18. Grabherr MG, Haas BJ, Yassour M, et al,. Full-length transcriptome assembly from RNA-Seq data without a reference genome. Nature Biotechnol 2011; 29: 644-652.
19. Parker BC, Annala MJ, Cogdell DE, et al,. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013; 123: 855-865.
20. Singh D, Chan JM, Zoppoli P, et al,. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337: 1231-1235.
21. Williams SV, Hurst CD, Knowles MA,. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013; 22: 795-803.
22. Shaw AT, Yeap BY, Mino-Kenudson M, et al,. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
23. Cappellen D, De Oliveira C, Ricol D, et al,. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genet 1999; 23: 18-20.
24. Chesi M, Nardini E, Brents LA, et al,. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet 1997; 16: 260-264. (Pubitemid 27280209)
25. Weiss J, Sos ML, Seidel D, et al,. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
26. Lamont FR, Tomlinson DC, Cooper PA, et al,. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011; 104: 75-82.
27. Wu YM, Su F, Kalyana-Sundaram S, et al,. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013; DOI: 10.1158/2159-8290.CD-13-0050.
28. Agrawal N, Frederick MJ, Pickering CR, et al,. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154-1157.
29. Stransky N, Egloff AM, Tward AD, et al,. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-1160.
30. Inaki K, Hillmer AM, Ukil L, et al,. Transcriptionalconsequences of genomic structural aberrations in breast cancer. Genome Res 2011; 21: 676-687.